- Home
- VYX vs DNTH Comparison
VYX vs DNTH Comparison
Compare VYX & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYX
- DNTH
- Stock Information
- Founded
- VYX 1881
- DNTH 2015
- Country
- VYX United States
- DNTH United States
- Employees
- VYX N/A
- DNTH N/A
- Industry
- VYX
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- VYX
- DNTH Health Care
- Exchange
- VYX Nasdaq
- DNTH Nasdaq
- Market Cap
- VYX 1.8B
- DNTH 1.5B
- IPO Year
- VYX N/A
- DNTH N/A
- Fundamental
- Price
- VYX $12.79
- DNTH $37.47
- Analyst Decision
- VYX Strong Buy
- DNTH Strong Buy
- Analyst Count
- VYX 5
- DNTH 9
- Target Price
- VYX $14.20
- DNTH $61.57
- AVG Volume (30 Days)
- VYX 1.4M
- DNTH 987.2K
- Earning Date
- VYX 11-06-2025
- DNTH 11-06-2025
- Dividend Yield
- VYX N/A
- DNTH N/A
- EPS Growth
- VYX N/A
- DNTH N/A
- EPS
- VYX 7.32
- DNTH N/A
- Revenue
- VYX $2,677,000,000.00
- DNTH $4,854,000.00
- Revenue This Year
- VYX N/A
- DNTH N/A
- Revenue Next Year
- VYX N/A
- DNTH N/A
- P/E Ratio
- VYX $1.74
- DNTH N/A
- Revenue Growth
- VYX N/A
- DNTH 17.87
- 52 Week Low
- VYX $7.55
- DNTH $13.37
- 52 Week High
- VYX $15.34
- DNTH $38.59
- Technical
- Relative Strength Index (RSI)
- VYX 47.21
- DNTH 83.36
- Support Level
- VYX $12.46
- DNTH $36.00
- Resistance Level
- VYX $13.06
- DNTH $24.81
- Average True Range (ATR)
- VYX 0.40
- DNTH 2.71
- MACD
- VYX -0.03
- DNTH 1.15
- Stochastic Oscillator
- VYX 25.19
- DNTH 92.90
About VYX NCR Voyix Corporation
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.